A2A receptor antagonists have been proposed as neuroprotective treatments and A2A deficiency attenuates brain injury during ischemia [39,40], therefore, we tested the effect of A2A receptor antagonist SCH442416 on spontaneous adenosine release during I-R injury. This evidence concerns the gene IGKV2D-29 and ischemia.